Investor's Business Daily on MSN

Travere, Ligand hammered on a surprise delay for their linchpin drug

Travere Therapeutics shares crashed Tuesday as investors digested a potential delay for its drug, Filspari, in treating a ...
Seeking Alpha

Travere Therapeutics Provides Corporate Update and 2025 Outlook

Received 693 new patient start forms for FILSPARI ® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA ...